Machine Learning

At Agrishow 2026, EAVISION's new J150 drone showcases advanced AI and terrain-following tech to tackle Brazil's unique agricultural challenges.

As it preps a first-in-human study for a deadly genetic heart disease, Nuevocor brings on gene therapy veteran Dr. Monica Shah to lead the charge.

A new report reveals sophisticated 'cloaking' is the top reason for ad account bans, highlighting a multi-billion dollar shadow war in online advertising.

Venture capital firm Altira cashes out on a major energy tech success, as simulation leader ResFrac secures new funding to expand into geothermal energy.

Event tech firm Showpass just hired a top NBCUniversal exec. See how its unique 'Dream Job' initiative is fueling its ambitious global expansion.

Ascidian Therapeutics to present first human safety data for its Stargardt disease drug, a new RNA editing technology with broad potential for genetic diseases.

Florida's only GitHub Copilot Dev Days, sponsored by NLP Logix, brings industry giants to Jacksonville to explore the future of AI-assisted development.

A new collaboration aims to merge drugs with AI-driven apps, creating a novel class of therapy that could revolutionize treatment, starting with rare cancers.

Zurich launches a major AI-focused capability center in Hyderabad, signaling a strategic shift to harness Indian tech talent for global insurance innovation.

Swedish firm pureSignal partners with Icelandic distributor, bringing AI-driven predictive maintenance to the region's key energy and industrial sectors.

Amity University's international workshop leverages AI and global expertise to forge a new path for digital accessibility in India's higher education.

Encoded Therapeutics is set to unveil pivotal data on ETX101, a one-time gene therapy showing promise in not just stopping seizures but reversing developmental delays.

Biotech firm Tr1X unveils promising data for its novel cell therapies, offering a scalable new approach to treating autoimmune diseases like MS and GvHD.

Dyno Therapeutics is using AI to design 'smart' viral vectors, promising safer, more effective treatments for untreatable genetic diseases.

Biotech firm Cellectis presents a new epigenetic platform that silences genes without cutting DNA, a potentially safer approach for cancer and liver disease.

Set to unveil its "best of both" PRINT™ platform, Addition Therapeutics aims to cure diseases from Fabry to HIV with a single, durable genetic medicine.

Umoja Biopharma's UB-VV500 aims to revolutionize myeloma care by creating a dual-antigen CAR T therapy directly inside the patient's body.

Cambridge biotech to unveil AI-powered LNP platform at ASGCT 2026, targeting fat and T-cells to unlock new treatments for obesity and cancer.

A new therapy programs immune cells inside the body to fight disease. Sail Biomedicines is pioneering this approach to offer a potential cure for autoimmunity.

VisionSys AI is in talks for a massive $90M investment to pivot to BCI tech, but with its stock down 96%, can this lifeline conquer the final frontier?